Linked Life Data

14716140

Source:http://linkedlifedata.com/resource/pubmed/id/14716140

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2004-1-12
pubmed:abstractText
The combination of docetaxel and cisplatin is one of the standard chemotherapy regimens which has been shown to improve survival and quality of life in patients with advanced non-small cell lung cancer (NSCLC). Docetaxel has therefore been administered by several groups in the neoadjuvant setting in stage-III disease. In combination with cisplatin, the response rate, the complete resection rate and the pathological response rate were similar as in other regimens, postoperative morbidity and mortality, however, seemed reduced when compared with combinations including mitomycin C. Furthermore, there was an association of the chemotherapy activity in mediastinal lymph nodes of patients with a NSCLC (stage IIIA) and overall survival. Based on these results, the cytostatic combination of docetaxel/cisplatin has been chosen for further use in large randomized studies.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0378-584X
pubmed:author
pubmed:copyrightInfo
Copyright 2003 S. Karger GmbH, Freiburg
pubmed:issnType
Print
pubmed:volume
26 Suppl 7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
33-6
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
[Docetaxel in neoadjuvant therapy of early-stage non-small cell carcinoma].
pubmed:affiliation
Institut für Medizinische Onkologie, Inselspital, Universität Bern. daniel.betticher@insel.ch
pubmed:publicationType
Journal Article, Comparative Study, English Abstract, Review